BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

Elsewhere in the migraine prevention field, Lundbeck markets the infused drug Vyepti in the crowded CGRP inhibitor space. The ...

Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive ...

After a preliminary look at the numbers, the company says revenues in its fiscal 2023 and 2024 years "may have been ...

Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case ...

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

For all of the groundbreaking advancements in cancer treatment over the last decades, the first step for tackling almost all solid tumors is still surgery. | For all of the groundbreaking advancements ...

"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...

During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and the Department of Health ...

Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...